Overview
PT-141, also known by its clinical name bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II, itself a modified analog of the naturally occurring hormone alpha-melanocyte-stimulating hormone (α-MSH). It belongs to a class of compounds known as melanocortin receptor agonists, meaning it is designed to interact with melanocortin receptors found throughout the body and brain. Unlike many other compounds in this research space, PT-141 is notable for acting through a central nervous system pathway rather than a purely vascular one, which has made it a subject of particular scientific interest. Researchers have studied PT-141 in the context of melanocortin system signaling, and it has appeared in published literature examining endocrine and metabolic peptide compounds. PT-141 is intended strictly for laboratory and research purposes and is not approved or intended for human consumption outside of regulated clinical settings.
Research & Bioactivity
PT-141, also known as bremelanotide, is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that acts on melanocortin receptors, particularly MC3R and MC4R, in the central nervous system. Researchers have studied PT-141 primarily in the context of sexual function and desire, with investigations exploring its effects on arousal-related signaling pathways in both male and female subjects across animal models and clinical trial settings. Studies have examined its potential relevance to hypoactive sexual desire disorder (HSDD) in women, with clinical research evaluating how melanocortin receptor activation in the brain may influence subjective measures of sexual motivation and receptivity. Research has also investigated whether PT-141 may hold relevance for sexual dysfunction in men, with published literature reviewing its receptor-mediated mechanisms as distinct from peripherally acting compounds. Beyond sexual biology, PT-141 has appeared in broader reviews of therapeutic peptides covering metabolic, endocrine, and gerontological research contexts, reflecting interest in melanocortin-targeting compounds across multiple areas of physiology.
Published Research
Quantification of "Mercy Sex" in Heterosexual Women.
Guptan N, Simon JA — 2026
Women with hypoactive sexual desire disorder (HSDD) lack the thoughts, desire, or receptivity to sexual desire, causing personal difficulty and distress (DSM IV-TR). However, HSDD clinical trials evaluating testosterone therapy, flibanserin, and bremelanotide spanning nearly a decade show women with HSDD, encompassing low to no sexual desire, are still engaging in sexual activity. We aimed to define this sexual activity as "mercy sex", quantify its frequency, and provide hypothetical explanations for this behavior. We reviewed baseline data on sexually satisfying events (SSEs) from a representative convenience sample of published, peer-reviewed, prospective, randomized, placebo-controlled trials of women with HSDD. Baseline data were assessed across time, age, reproductive status, and geography. Women in these studies engaged in "mercy sex" about 2.5 times/month despite their documented HSDD. These results have important implications for further HSDD clinical research, as mercy sex frequency may skew therapeutic efficacy while having significant implications in calculating trial sample size, and assessing a clinically meaningful response to therapy, when SSEs are used as a primary endpoint. Although this paper explores only a biopsychosocial explanation for the phenomenon of mercy sex in clinical trials of HSDD therapies, it provides a valuable understanding that will benefit patients, clinicians, and researchers.
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
Renke G, Chinellato L — 2026
Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes. While several peptide drugs have undergone rigorous approval processes that evaluate both safety and efficacy, novel, unapproved compounds have emerged and are rapidly expanding into preventive medicine and performance enhancement. Our objective is to present the effects, clinical applications, safety profiles, and regulatory status of prominent peptides used to treat several conditions. We reviewed 106 articles, prioritizing systematic reviews, meta-analyses, and randomized controlled trials in the PubMed, ScienceDirect, and SciELO databases. Our results suggest that therapeutic peptides are a promising tool for treating type 2 diabetes and obesity, for skin rejuvenation, and as hormone analogs for specific diseases and conditions. Although these are strategic and innovative options that can improve health, performance, and longevity, further studies are needed before most new peptides can be used safely in humans.
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.
Tran L, Nguyen TD, Gad AG, Shaaban E, Tai TH, et al. — 2026
d-Amino acids, the non-natural enantiomers of l-amino acids, have emerged as powerful tools in peptide drug development due to their unique biochemical properties. Their resistance to proteolytic degradation, enhanced conformational rigidity, and reduced immunogenicity make them especially valuable in designing long-acting and receptor-selective therapeutics. Since the mid-20th century, more than 20 FDA-approved drugs have incorporated at least one d-amino acid into their structure, spanning indications from infectious diseases and endocrine disorders to rare dermatologic conditions and diagnostic imaging. These drugs include both natural products like gramicidin D and synthetic analogs such as desmopressin, leuprolide, bremelanotide, and etelcalcetide, the latter being the first fully d-amino acid peptide to receive FDA approval. This review traces the historical development and clinical adoption of d-amino acid-containing drugs, highlighting their mechanisms of action, therapeutic relevance across disease areas, and the technological innovations, particularly solid-phase peptide synthesis and conceptual advances such as mirror-image phage display, that enabled their advancement. As peptide therapeutics continue to evolve, d-amino acids-containing drugs are poised to play a central role in the next generation of targeted, stable, and high-precision pharmaceuticals.
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Mavrych V, Shypilova I, Bolgova O — 2026
BACKGROUND: Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline. OBJECTIVE: To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions. METHODS: A comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026. Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory documents, and preclinical studies were evaluated. A total of 20 primary sources were selected based on relevance, methodological quality, and contribution to understanding peptide mechanisms and clinical outcomes in aging populations. RESULTS: Nine peptides were identified spanning diverse aging interventions: metabolic restoration (tirzepatide), telomere biology (epitalon), dermal regeneration (GHK-Cu), tissue repair (BPC-157, TB-500), neuroprotection (Semax), growth hormone modulation (CJC-1295, ipamorelin), and sexual function (bremelanotide). FDA-approved agents demonstrated robust safety profiles from large-scale trials. Non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation. Significant knowledge gaps include optimal dosing regimens, combination therapy effects, and biomarkers for monitoring efficacy. CONCLUSION: Therapeutic peptides offer mechanistically diverse approaches to multiple aging hallmarks. While FDA-approved agents demonstrate clinical potential, investigational peptides require rigorous validation through well-designed clinical trials to establish safety and efficacy for healthspan extension.
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?
Pfaus JG, Balon R